Display options
Share it on

Cytotherapy. 2021 Oct 20; doi: 10.1016/j.jcyt.2021.09.006. Epub 2021 Oct 20.

The importance of evaluating differences in HES formulations used in hematopoietic progenitor cell cryopreservation.

Cytotherapy

Michael Halpenny, Nishaka William, Heidi Elmoazzen, Antonio Giulivi, Lisa Martin, Donna Perron, Christopher Bredeson, Linda Hamelin, Lothar Huebsch, Lin Yang, Paul Birch, Jason P Acker

Affiliations

  1. Canadian Blood Services, Ottawa, Ontario, Canada.
  2. Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada.
  3. Canadian Blood Services, Ottawa, Ontario, Canada; The Ottawa Hospital, Ottawa, Ontario, Canada.
  4. The Ottawa Hospital, Ottawa, Ontario, Canada.
  5. Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada; Centre for Innovation, Canadian Blood Services, Edmonton, Alberta, Canada. Electronic address: [email protected].

PMID: 34688545 DOI: 10.1016/j.jcyt.2021.09.006

[No abstract available.]

Conflict of interest statement

Declaration of Competing Interest The authors have no conflicts of interest to disclose.

Publication Types